In support with this notion, a randomized Phase III clinical trial has further confirmed the clinical value of cabozantinib, a multityrosine kinase inhibitor targeting MET, VEGFR, and AXL in RCC patients who had progressed following VEGFR inhibitor therapy including sunitinib (Géczi et al., 2015). Here, AXL is linked to renal cell adenocarcinoma.